Analyst Update: Depomed, LivePerson, and YY Inc.

Analysts adjusted their ratings on Depomed Inc (NASDAQ:DEPO), LivePerson, Inc. (NASDAQ:LPSN), and YY Inc (ADR) (NASDAQ:YY)

May 12, 2015 at 12:42 PM
facebook X logo linkedin

Analysts are weighing in today on drugmaker Depomed Inc (NASDAQ:DEPO), digital engagement specialist LivePerson, Inc. (NASDAQ:LPSN), and social communication platform YY Inc (ADR) (NASDAQ:YY)Here's a quick look at today's brokerage notes on DEPO, LPSN, and YY. 

  • RBC cut its price target on DEPO to $26 from $29 while underscoring an "outperform" rating, after the firm revealed a wider-than-forecast first-quarter loss. At last check, the shares of Depomed Inc were 17.7% lower at $20.09, paring the stock's year-to-date lead to 24.7%. Short sellers are likely cheering today's negative price action, as short interest on DEPO rose 6% over the last two reporting periods. Shorted shares now account for about 20% of the stock's available float, which would take seven sessions to cover, at average trading volumes. Of course, given today's big drop, DEPO is currently on the short-sale restricted (SSR) list. Elsewhere, the brokerage bunch is generally optimistic on DEPO, as 80% of covering analysts rate it a "buy" or "strong buy."
  • The shares of LPSN are 12.2% lower at $8.31 -- and earlier touched a two-year low of $8.10 -- after the firm cut its 2015 revenue forecast. In response, no fewer than four brokerage firms doled out negative notes on the stock -- including Credit Suisse, which downgraded its rating to "neutral" from "outperform" while slashing its price target to $8 from $19. Similarly, Roth Capital cut its target to $14 from $23, saying, "growth and earnings will ... suffer significant pressure near-term" due to the loss of key client AT&T Inc. (NYSE:T). Technically speaking, today's bearish gap is more of the same for LivePerson, Inc., as the shares have retreated over 41% year-to-date. What's more, the post-earnings sell-off has earned the stock a spot on the SSR list, alongside DEPO. Heading into today's session, the analyst community was divided on LPSN, as half of covering analysts rated it a "strong buy," with the remaining half doling out "hold" opinions. 
  • It's a similar story for YY, which woke up to a pair of negative brokerage notes after the company's first-quarter earnings failed to meet the Street's expectations. Specifically, Pacific Crest cut its price target to $80 from $91, while Piper Jaffray slashed its target to $88 from $109. (Both brokerage firms kept their "overweight" opinions on the stock.) On the charts, the shares of YY Inc have fallen 6.5% today -- last seen at $64.46 -- trimming their year-to-date lead to just 3.4%. The stock is now testing support at its 20-day moving average, which hasn't been breached on a daily closing basis since late March. Looking to the options pits, speculators were apparently bracing for a negative earnings reaction, as YY's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.23 stands in the 92nd annual percentile. 

Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.

Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!




Rainmaker Ads CGI